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INTRODUCTION 
Drug-drug interactions (DDIs) is defined as the change of 
efficacy and toxicity of some drugs in the presence of 
other drugs (Shetty et al., 2018). The alterations occure 
both in pharmacokinetics (absorbtion, distribution, 
metabolism, and excretion) and pharmacodynamics 
(sinergism, antagonism, and competition in receptors) 
phase (Kulkarni et al., 2013; Palleria et al., 2013). In the 
clinical settings, DDIs is the main source of adverse drug 
event (Somogyi-Vegh et al., 2019). A recent meta-analysis 
of several studies reports that DDIs has contributed to 
1.1-5% of hospitalization and 0.25-25% of the adverse 
drug reaction related to hospitalization (Dechanont et al., 
2014; Ismail et al., 2018). In outpatient settings, there is a 
lack documentation of DDIs and its prevalence is 
reported lower than in hospitalized patients because they 
are usually prescribed less drug combination (Vaidhun 
& Sathish, 2011).  However, if they are prescribed with 
polypharmacy the potential of DDIs occurence will also 
rise. 
Bronchopneumonia is one of life-threatning pneumonia 
manifestation commonly occur in children under 5 y.o. 
As the treatment of pneumonia, causative management 
using antibiotics and symptomatic drugs like antitusive, 
expecorant, antihistamine, analgesic-antipyretic used in 
bronchopneumonia management (Harris et al., 2011; 
Chang et al., 2014).  Hence, high combination drugs 
potentially prescribed to the children with 
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potential DDIs on the prescriptions of children with 
bronchopneumonia. An observational and cross-sectional study was 
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The majority of potential DDIs was pharmacodynamic interaction 
(76.12%) with the most frequently involved drug pair was Ephedrine-
Salbutamol (29.85%). Children outpatients with bronchopneumonia 
are at risk of potential DDIs, especially to minor and moderate 
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bronchopnaumonia and its leading to the occurence of 
DDIs. The DDIs identification in bronchopneumonia 
prescriptions will optimize the outcome therapy and 
prevent the incidence of adverse drug reactions (Noor et 
al., 2019). This study was aimed to observe the potential 
DDIs on the prescriptions of children with 
bronchopneumonia. 
 
MATERIALS AND METHODS 
An observational and cross-sectional study was 
conducted on outpatient children with 
bronchopneumonia prescriptions during 2017 at a 
Hospital in Bangkalan, Madura Island, Indonesia. Study 
began after obtaining permition from the hospital. The 
Inclusion criteria were prescriptions of outpatient 
children age 0-14 y.o. diagnosed with 
bronchopneumonia without any infection comorbidities. 
Prescriptions contained one or two drugs with different 
route of administration were excluded. Potential for 
DDIs were identified by online drug interaction checkers 
from www.drugs.com. The drugs that not available in 
the database were than identified by www.drugbank.ca. 
The prescriptions contained drugs that not listed in that 
two online applications were also excluded. The potential 
DDIs then classified based on its severity (minor, 
moderate, and major) and mechanism (pharmacokinetic 
and pharmacodinamic). The management suggestion 
from the online applications also included. 
 
RESULTS AND DISCUSSION 
During the period of study, a total of 158 prescriptions 
met the inklusions criteria. Of that, 72 prescriptions were 
excluded due to varoous reasons; 9 prescriptions only 
contained of one drugs, 3 prescriptions contained of two 
drugs with different route; 10 prescriptions consisted of 
probiotics; and 50 remaining contained of herbal 
medicine like succus liquiritae and echinaceae extract that 
not available in the the two online-application used.  The 
remaining 86 prescriptions were analyzed for the 
potential DDIs. The prevalence of potential DDIs based 
on gender, age, and number of drug prescribed showed 
in patients characteistics as presented in Table I. 
Table I. Patients characteristics 
Characteristics 
N (%) 
Total (%) Potential 
DDIs 
No Potential 
DDIS 
Gender 
Female 
Male 
 
19 (22.09) 
23 (26.74) 
 
24 (27.91) 
20 (23.26) 
 
43 (50.00) 
43 (50.00) 
Total 42 (48.84) 44 (51.16) 
86 
(100.00) 
Age (years) 
<1 
1-5 
6-10 
11-14 
 
13 (15.12) 
21 (24.42) 
5 (5.81) 
3 (3.49) 
 
2 (2.33) 
35 (40.70) 
7 (8.14) 
0 (0.00) 
 
15 (17.44) 
56 (65.12) 
12 (13.95) 
3 (3.49) 
Total 42 (48.84) 44 (51.16) 
86 
(100.00) 
Number of drug 
prescribed 
<5 
5-10 
>10 
 
 
30 (34.88) 
7 (8.14) 
5 (5.81) 
 
 
10 (11.63) 
21 (24.42) 
13 (15.12) 
 
 
40 (46.51) 
28 (32.56) 
18 (20.93) 
Total 42 (48.84) 44 (51.16) 
86 
(100.00) 
 
Generally, the prevalence of potential DDIs is linear to the 
number of drug prescribed as Loya et al. (2009) reported 
that 46.2% dan 72.3% of polypharmacy had at least one 
potential DDIs. However, in this study the majority 
potential DDIs observed in the prescriptions contained 
less than five drugs. This discrepancy might be due to the 
prescribing culture and formulary used in the hospital. 
Out of the 42 potential DDIs found, most of them had 
moderate (80.95%) and minor (73.80%) severity that is 
sufficiently to warn us to have a monitoring for the 
potential dangerous, as shown in Figure 1. 
 
Figure 1. Severity of Potential DDIs 
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The prevalence of potential DDIs, its manifestations, and 
suggested management predominantly occur in the 
pharmacodynamic phase, as presented in Table II. The 
higher number of pharmacodynamics DDIs are 
probably due to the drug combinations prescribed is 
purposed to enhance the efficacy (Patel et al, 2014). The 
pair of ephedrine+salbutamol was counted 29.85% of 
pharmacodynamics DDIs and potentially harm to 
patients as it has moderate severity. The manifestation is 
similar to pseudoephedrine+salbutamol which was 
observed 4.48% of pharmacodynamics DDIs in this 
study. The administration of beta-2 agonists together 
with other adrenergic agents may result in the increase of 
cardiovascular side effects including escalation of pulse 
rate and systolic or diastolic blood pressure as well as 
ECG changes such as flattening of the T wave, 
prolongation of the QTc interval, and ST segment 
depression. These effects may be more common when 
the drugs are administered systemically or when 
recommended dosages are exceeded (Khalilian et al., 
2016). A meta-analysis by Salpeter et al. (2004) reported 
that beta-2 agonist use in patients with obstructive airway 
disease increases the risk for cardiovascular adverse 
events from three days to one year. The manifestation 
occure were an increase in heart rate and potassium 
concentrations depletion. Therefore, the oral concomitant 
use of ephedrine+salbutamol in children with 
bronchopneumonia must be counted for its benefit and 
risk. Use salbutamol in local route like inhaler will 
minimize the risk of cardiovascular event.   
Another pharmacodynamic DDIs that need to be 
considered was from the pair of 
dexamethasone+teophyline. The co-administration of 
theophylline and corticosteroids theoretically may 
potentiate the risk of hypokalemia due to additive 
potassium-lowering effects. Theophylline inhibits 
adenosine receptors and blocks phosphodiesterase 
causing rised cyclic adenosine monophosphate resulting 
in increased levels of adrenergic activation and 
catecholamine release at larger dose (Barnes, 2010). 
Elevated catecholamine concentrations will lead to 
adverse effects such as metabolic acidosis, 
hyperglycemia, cardiac arrhythmias, and hypokalemia 
(Kardalas et al., 2018).  Additionally, corticosteroids 
conduce sodium retention through the increase of 
sodium tubular absorption and potassium excretion. 
Sodium retention and potassium loss may result in 
hypokalemic alkalosis in patients receiving 
glucocorticoids (Nasralla et al., 2010). Consequently, if the 
benefits outweight the drawbacks, the use of 
dexamethasone and theophylline in children with 
bronchopneumonia should be followed by monitoring 
in potassium levels and the cardiovascular events (Zec et 
al., 2016). 
In the pharmacokinetics phase, the most common DDIs 
observed was ephedrine+vitamin C. Acidic urine 
increases the urinal elimination of ephedrine. However, 
the severity is minor and the clinical significance is 
unknown. 
Table II. Prevalence of potential DDIs 
Drug pairs 
N (%) / 
severity 
Potential 
Manifestasion 
Management 
Pharmacokinetics DDIs 
Ephedrine-Vitamin 
C 
9 (13.43) 
/ Minor 
The effect of 
ephedrine may be 
decreased 
Considering 
for drug 
subtitution 
Phenytoin-
Dexamethasone 
2 (2.99) / 
Moderate 
The effect of 
dexamethasone 
may be decreased 
Considering 
for drug 
subtitution 
Phenytoin-
Paracetamol 
2 (2.99) / 
Moderate 
The potential 
hepatotoxicity  of 
paracetamol may be 
increased and its 
pharmacological 
effects may be 
decreased 
Monitoring on 
liver function 
Total 13 (19.40) 
Pharmacodynamics DDIs 
Chlorphenyramine
- Domperidone 
1 (1.49) / 
Unknown 
The effect on 
cardiovascular 
may be increased 
Monitoring of 
the presence of 
arrhythmia 
Chlorphenyramine
- Codein 
1 (1.49) / 
Moderate 
The effect on CNS 
may be increased 
Monitoring on 
respiration 
function 
Dexamethasone 
+ Salbutamol 
9 (13.43) 
/ Minor 
The effect on 
cardiovascular 
may be increased 
Monitoring of 
the presence of 
arrhythmia 
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Dexamethasone 
+ Teophyline 
4 (5.97) / 
Moderate 
The effect on 
cardiovascular 
may be increased 
Monitoring 
for altered 
efficacy and 
safety of 
theophylline 
and altered 
serum 
potassium 
Ephedrine + 
Salbutamol 
20 (29.85) / 
Moderate 
The effect on 
cardiovascular 
may be increased 
Monitoring for 
blood pressure 
and heart rate 
Ephedrine -
Teophylin 
1 (1.49) / 
Minor 
The potential side 
effects like nausea, 
vommiting, 
tachycardia and 
insomnia may be 
increased 
Monitoring of 
the presence of 
side effects 
Methylprednisolon 
+ Salbutamol 
9 (13.43) 
/ Minor 
The hypokalemia 
risk and the effect 
on cardiovascular 
may be increased 
Monitoring for 
serum 
potassium 
level and the 
presence of 
arrhythmia 
Prednison- 
Salbutamol 
1 (1.49) / 
Minor 
The hypokalemia 
risk and the effect 
on cardiovascular 
may be increased 
Monitoring for 
serum 
potassium 
level and the 
presence of 
arrhythmia 
Pseudoephedrine- 
Salbutamol 
3 (4.48) / 
Moderate 
The effect on 
cardiovascular 
may be increased 
Monitoring for 
blood pressure 
and heart rate 
Salbutamol- 
Teophyline 
1 (1.49) / 
Moderate 
The hypokalemia 
risk and the effect 
on cardiovascular 
may be increased 
Monitoring for 
serum 
potassium 
level and the 
presence of 
arrhythmia 
Cetirizin- 
Sodium 
Valproate 
1 (1.49) / 
Moderate 
The effect on CNS 
may be increased 
Monitoring for 
cognitif 
function 
Total 53 (76.12) 
Unknown mechanism DDIs 
Dexamethasone
- Ephedrine 
2 (2,99) / 
Minor 
The effect of 
dexamethasone 
may be decreased 
Considering 
for drug 
subtitution 
Domperidone-
Paracetamol 
1 (1,49) / 
Unknown 
The serum level of 
domperidone may 
be increased 
Considering 
for drug 
subtitution 
Total 3 (4.48) 
Total 67 (100.00) 
 
Apart from the result above, this study has several 
limitations. As this study showed the potential for DDIs 
in the prescriptions, the actual occurr of DDIs in the 
patients could not be determined because the study was 
a single point cross-sectional and out-patient based. 
Moreover, herbal medicine and probiotics-contained 
prescriptions could not be determined for the DDIs. 
Therefore, future studies on potential and actual 
occurrence DDIs in outpatient children with 
bronchopneumonia in future still need to be conducted. 
CONCLUSION 
A considerable prevalence of potential DDIs has been 
observed in children outpatients with 
bronchopneumonia (48.84%) where moderate potential 
DDIs were the most common. Moreover, the use of 
probiotics and herbal medicine in bronchopneumonia 
treatments still need to be considered related unknown 
potential DDIs. Prescriptions screening for potential 
DDIs followed by monitoring of therapeutical effects and 
associated adverse drug events will optimize patient 
safety. 
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